Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the effects of antipsychotics on a delayed radial maze task in the rat

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

The cognitive impairments evident in many schizophrenics are related to the severity of their negative symptoms and ability to function in society. Drugs that alleviate cognitive impairments, in addition to other psychotic symptoms, may have an important influence on treatment outcome and the course of the illness.

Objectives

A delayed non-match to sample task conducted in an eight-arm radial maze was used to determine the influence of four atypical antipsychotics (olanzapine, ziprasidone, risperidone, and clozapine), as well as a typical neuroleptic (haloperidol) on consolidation processes in healthy rats.

Method

Well-trained rats were required to recall after a 7-h delay where they had received food pellets during an information phase (first four arm choices) in order to obtain the remaining food pellets during a retention phase (second four arm choices).

Results

The total number of errors that occurred during the retention session increased with increasing delay periods from 0 to 7 h. When administered orally immediately after the information phase, olanzapine (3 and 5 mg/kg) and risperidone (0.1 mg/kg) significantly reduced the number of errors made during the retention phase. Under the same conditions, clozapine, ziprasidone and haloperidol failed to affect the total number of retention phase errors.

Conclusion

Some atypical antipsychotics, such as olanzapine and risperidone, improve consolidation processes and may alleviate the cognitive impairments associated with schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2a–e.
Fig. 3a–e.
Fig. 4.

Similar content being viewed by others

References

  • Aravagiri M, Marder SR (2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology 159:424–431

    Article  CAS  PubMed  Google Scholar 

  • Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369–377

    Google Scholar 

  • Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101

    Article  CAS  PubMed  Google Scholar 

  • Bakshi VP, Geyer MA (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198–201

    CAS  PubMed  Google Scholar 

  • Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117–124

    Google Scholar 

  • Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495–529

    Article  PubMed  Google Scholar 

  • Beatty WW, Rush JR (1983) Spatial working memory in rats: effects of monoaminergic antagonists. Pharmacol Biochem Behav 18:7–12

    Article  CAS  Google Scholar 

  • Breier A, Schreiber JL, Dyer J, Pickar D (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 48:239–246

    CAS  PubMed  Google Scholar 

  • Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Article  CAS  PubMed  Google Scholar 

  • Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, Cohen ML (2001) Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 430:341–349

    Article  CAS  PubMed  Google Scholar 

  • Chengappa KN, Pollock H, Levine J, Kirshner MA, Brar JS, Zoretich RA (2000) Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20:311–316

    Google Scholar 

  • Dawson LA, Huy Q, Nguyen BS, Li P (2001) The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25:662–668

    Article  CAS  PubMed  Google Scholar 

  • Grant S, Fitton A (1994) Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48:253–273

    CAS  PubMed  Google Scholar 

  • Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330

    CAS  PubMed  Google Scholar 

  • Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799–804

    CAS  PubMed  Google Scholar 

  • Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325–339

    Article  CAS  PubMed  Google Scholar 

  • Levin ED, Johansson PE (1988) Cognitive effects of long-term chronic neuroleptic drug administration. Toxicologist 8:77

    Google Scholar 

  • Markowska A, Buresova O, Bures J (1983) An attempt to account for controversial estimates of working memory persistence in the radial maze. Behav Neural Biol 38:97–112

    CAS  PubMed  Google Scholar 

  • Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233–255

    CAS  PubMed  Google Scholar 

  • Moore NA (1999) Behavioral pharmacology of the new generation of antipsychotic agents. Br J Psychiatry 174:5–11

    Google Scholar 

  • Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H (1997) Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58: 37–44

    CAS  Google Scholar 

  • Nowakowska E, Chodera A, Kus K, Rybakowski J (1999) Some behavioural effects of risperidone in rats: comparison with haloperidol. Eur Neuropsychopharmacol 9:421–426

    Article  CAS  PubMed  Google Scholar 

  • Pilcher JJ, Sessions GR, McBride SA (1997) Scopolamine impairs spatial working memory in the radial maze: an analysis by error type and arm choice. Pharmacol Biochem Behav 58:449–459

    CAS  PubMed  Google Scholar 

  • Ploeger GE, Spruijt BM, Cools AR (1992) Effects of haloperidol on the acquisition of a spatial learning task. Pharmacol Behav 52:979–983

    CAS  Google Scholar 

  • Prakash C, Kamel A, Anderson W, Howard H (1997) Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C and 3H-labeled ziprasidone. Drug Metab Dispos 25:206–218

    CAS  PubMed  Google Scholar 

  • Purdon SE (1999) Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 35 S51–60

    Google Scholar 

  • Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD (2000) Neuropsychological change in early schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57:249–258

    CAS  PubMed  Google Scholar 

  • Pussinen R, Sirvio J (1999) Effects of d-cycloserine, a positive modulator of N-methyl-d-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol 13:171–179

    CAS  PubMed  Google Scholar 

  • Rogers DC, Robinson TL, Quilter CA, Hunter AJ, Routledge C, Hagan JJ (1999) Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br J Pharmacol 127:22P

    Google Scholar 

  • Schmidt AW, Lebel LA, Howard HR, Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197–201

    CAS  PubMed  Google Scholar 

  • Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583–594

    Google Scholar 

  • Skarsfeldt T (1996) Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 124:126–133

    Google Scholar 

  • Spohn HE, Strauss ME (1989) Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98:367–380

    CAS  PubMed  Google Scholar 

  • Staubli U, Rogers G, Lynch G (1994) Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91:777–781

    CAS  PubMed  Google Scholar 

  • Strijkstra AM, Bolhuis JJ (1987) Memory persistence of rats in a radial maze varies with training procedure. Behav Neural Biol 47:158–66

    CAS  PubMed  Google Scholar 

  • Tollefson GD (1996) Cognitive function in schizophrenic patients. J Clin Psychiatry 57: 31–39

    CAS  Google Scholar 

  • Xi-Ming L, Perry KW, Wong DT, Bymaster FP (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136:153–161

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Mail Code No. 0510, Indianapolis, IN 46285, USA

    Mary C. Wolff & J. David Leander

Authors
  1. Mary C. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. David Leander
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary C. Wolff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolff, M.C., Leander, J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology 168, 410–416 (2003). https://doi.org/10.1007/s00213-003-1449-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-003-1449-3

Keywords

Search

Navigation